INTRODUCTION
Elevated serum cholesterol concentrations, particularly low-density lipoprotein cholesterol (LDL-C), is a recognized risk factor for coronary heart disease (CHD), and numerous interventional studies have shown that lowering LDL-C delays the progression of atherosclerotic lesions and reduces cardiovascular mortality and morbidity associated with CHD. 1 As a result, current guidelines for the prevention of CHD recommend the use of lipid-modifying therapy in patients with dyslipidemia. However, several observational studies have shown that a significant proportion of patients do not attain recommended LDL-C concentration targets despite treatment with statins. [5] [6] [7] [8] Such findings highlight the need for more effective lipid-lowering strategies, which could include the use of more aggressive initial therapy, more potent agents, dose adjustment during treatment, or combination therapy using agents with different mechanisms of action.
Pitavastatin is a novel, highly potent statin that has been shown to provide significant reductions in total cholesterol, LDL-C, and triglyceride concentrations in patients with hyperlipidemia 9 or heterozygous familial hypercholesterolemia. 10, 11 Pitavastatin has also been shown to produce sustained increases in HDL-C concentrations over 52 weeks. 12 Unlike other statins, pitavastatin does not undergo extensive metabolism by cytochrome P450 isoenzymes, and hence the potential for interactions with drugs that are metabolized by cytochrome P450 is low. 
MATERIALS AND METHODS

Patients
The inclusion and exclusion criteria of the study have been described in detail previously. 
Study Design
The study was a 44-week, double-blind, doubledummy, parallel-group, active-controlled extension study in patients who had completed the core study. It was conducted at 24 centers (predominantly in lipid clinics, cardiology clinics, and university hospitals) in Denmark, the Netherlands, Spain, Sweden, and the United Kingdom.
During the core study, patients were randomized 2:1 to receive pitavastatin 4 mg or simvastatin 40 mg. Randomization was performed using an interactive voice recognition system at each center. Patients entering the extension study were maintained on the same drug they had received during the core study. 
Outcome Measures
The primary lipid-related endpoints in the ratio, and hs-CRP levels. All lipid analyses were performed at a central laboratory.
Safety and Tolerability
Treatment-emergent adverse events (TEAE), defined as any event with onset on or after the first dose of study drug, and serious TEAE were recorded throughout the study. All such events were coded by system organ class preferred term using the Medical Dictionary and vital signs.
Statistical Analyses
No formal sample size calculation was performed for this extension study because the number of patients entering the study was dependent on the number completing the core study and agreeing to enter the extension study. It was anticipated that this would be approximately 270 patients.
Efficacy analyses were performed on the efficacy population, which consisted of all patients who received at least one dose of study medication and had at least one lipid assessment during the study. Analyses of safety data were performed on the safety population, which included all patients who received at least one dose of study medication.
For the primary efficacy variables, the proportions of patients attaining NCEP and EAS LDL-C targets and NCEP non-HDL-C targets at weeks 16 and 44 were summarized by visit. For patients who withdrew before these times, the last available LDL-C concentration was used to assess whether targets had been attained.
No formal statistical analysis was performed.
Secondary efficacy variables were summarized in the same way.
RESULTS
Patient Flow and Baseline Characteristics
The first patient was enrolled into the Twenty-two patients withdrew during the study, mainly because of adverse events ( Figure 1 ).
Demographic characteristics of the patients entering the extension study are summarized in Table 1 . The characteristics of the patients in this study were similar to those of the total patient population enrolled in the core study.
14 There were no clinically relevant differences in demographic characteristics between the pitavastatin and simvastatin groups.
Efficacy
Attainment of EAS and NCEP Lipid Targets
The proportions of patients achieving NCEP or EAS targets for LDL-C concentrations at the end of the extension study are summarized in Table 2 . At the start of the extension study, the
Entered extension study N=178
Pitavastatin n=121
Simvastatin n=57
Dose maintained at 40 mg n=52
Dose increased to 80 mg n=5
Safety population n=52
Safety population n=121
Withdrawn from study: n=12 proportion of patients meeting NCEP step 9 targets was 84.3% with pitavastatin and 75.0%
with simvastatin among those who attained their targets during the core study, and 27.3% and 20.0%, respectively, among those who did not.
Secondary Efficacy Variables
Mean changes in secondary lipid variables and hs-CRP levels from baseline (start of the core study) to week 44 are summarized in Table 4 . were required to attain both their LDL-C and non-highdensity lipoprotein cholesterol (non-HDL-C) targets to achieve their NCEP step 9 target. In the remaining patients, the LDL-C target was regarded as the NCEP step 9 target. †In patients who withdrew before week 16 or 44, attainment of targets was assessed using the last available lipid determination. Table 4 . Changes in secondary lipid variables and high sensitivity C-reactive protein (hs-CRP) from baseline (start of the core study) to the start of the extension study (week 0) and from baseline to week 44 of the extension study in patients treated with pitavastatin or simvastatin. and source are credited.
